This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Martin Fogel, MD
Winnipeg, Canada

JAMA. 1989;261(20):2952.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The keen observation by Dr Smith¹ that American pharmaceutical companies have avoided the letter J as the first letter of a drug name is both fascinating and perplexing. As a Canadian viewing the situation, I see only two options available to my colleagues in the United States.

One solution is the formation of a congressional subcommittee with a mandate to investigate the etiology of "J discrimination."

The second solution is far more beneficial to both our countries. A quick perusal of the 1988 Compendium of Pharmaceuticals and Specialties reveals two brand names beginning with the letter J: Jay Max 500, a vitamin B complex with ascorbic acid, and Jectofer, injectable iron sorbitol.

America needs drug names that begin with the letter J. Canada needs a warmer climate. In the spirit of the forthcoming Free Trade Agreement between our two nations, I propose swapping our Canadian pharmaceuticals . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?